Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
The EVOLVE Short DAPT study is a prospective, single-arm study designed to assess the safety of 3-month DAPT in patients at high risk for bleeding, undergoing percutaneous coronary intervention with a SYNERGY stent system. All partiicpants must be treated with aspirin for the duration of the study and must also be treated with either clopidogrel, prasugrel, or ticagrelot for the 3 months following the procedure.
Who may be Eligible
Patients at high risk for bleeding who have had implantation of at least one SYNERGY stent within the preceding 3 calendar days.